Abstract 465P
Background
Diffuse intrinsic pontine glioma (DIPG) is one of the most aggressive pediatric central nervous system tumors, and currently, there are no curative treatment options available. With the increasing application of molecular diagnostics, more and more DIPG patients are recommended to undergo surgery; however, its correlation with dissemination needs to be better understood. Hence, we conducted this cohort to analyze the predictors of subsequent metastasis in pediatric DIPGs.
Methods
The final analysis included 142 pediatric (age ≤ 12) DIPG patients treated at Sanjiu Brain Hospital between January 2017 and September 2023. The data were retrospectively collected following the initial diagnosis. Patients were followed up for 6 months. The primary endpoint was the occurrence of subsequent metastasis. Univariable and multivariable logistic regression analyses were utilized to identify statistically significant predictors of subsequent dissemination. All statistical assessments were two-tailed, and only P < 0.05 was deemed to be statistically significant.
Results
Among 142 patients, 14 (9.9%) developed metastasis within the follow-up time. There were 77 (54.2%) males and 65 (45.8%) females. The median age was 7 years (ranging 1 - 12 years). The overall cohort demonstrated that surgery was the only predictor of dissemination both in univariable (OR 4.567, 95%CI 1.351 – 20.901, P = 0.024) and multivariable (OR 5.501, 95%CI 1.560 – 26.105, P = 0.014) analyses. However, subgroup analysis involving patients who received surgical intervention showed that biopsy was not superior nor inferior to resection in terms of relative risk for subsequent dissemination (16.7% vs. 15.8%).
Conclusions
Surgical intervention increases the relative risk of dissemination occurrence to four times more than those who did not receive surgery. Surgical intervention is crucial given the potential of molecular analysis leading to improved therapeutic options. Nonetheless, patients should be informed about the risks associated with surgery, including subsequent metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
586P - Clinical and molecular characteristics of colorectal adenosquamous carcinoma: A multicenter retrospective study
Presenter: Jun Huang
Session: Poster session 16
587P - Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500
Presenter: Francesco Schietroma
Session: Poster session 16
588P - Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
Presenter: Valentino Martelli
Session: Poster session 16
589P - Simultaneous resection versus staged resection for conversion surgery for initially unresectable colorectal liver metastasis: A prospective cohort study
Presenter: Jianmin Xu
Session: Poster session 16
590P - A deep-learning model to predict the completeness of cytoreductive surgery in colorectal cancer with peritoneal metastasis
Presenter: QingFeng Lin
Session: Poster session 16
Resources:
Abstract
591P - Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients
Presenter: Joel Kontiainen
Session: Poster session 16
592P - Survival analysis of surgical management options for goblet cell adenocarcinoma: Insights from machine learning clustering
Presenter: Marie Line El Asmar
Session: Poster session 16
593P - Treatment response and survival of patients with early onset colorectal cancer in the Netherlands
Presenter: Lauri Borghuis
Session: Poster session 16
594P - Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients (pts) from two adjuvant randomized trials
Presenter: Annalice Gandini
Session: Poster session 16
595P - Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium
Presenter: Jerome Desrame
Session: Poster session 16